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Background: Radiation to the inner ear may lead to (irreversible) sensorineural hearing loss. The purpose of this
study was to evaluate the long-term effect of radiotherapy on hearing in patients treated with Intensity
Modulated Radiation Therapy (IMRT), sparing the inner ear from high radiation dose as much as possible.
Methods: Between 2003 and 2006, 101 patients with head and neck cancer were treated with IMRT. Audiometry
was performed before, short-term, and long-term after treatment. Data were compared to normal hearing levels
according to the International Organisation for Standardization (ISO). Statistical analysis was done using repeated
measurements. None of the patients received chemotherapy.
Results: In 36 patients an audiogram at long-term follow-up (median 7.6 years) was available. The mean dose to the
cochlea was 17.8 Gy (1.0-66.6 Gy). A hearing deterioration of 1.8 dB at Pure Tone Average (PTA) 0.5-1-2 kHz (p = 0.11),
2.3 dB at PTA 1-2-4 kHz (p = 0.02), and 4.4 dB at PTA 8-10-12.5 kHz (p = 0.01) was found. According to the ISO, the
expected age-related hearing loss was 2.7, 4.8, and 8.8 dB at PTA 0.5-1-2 kHz, 1-2-4 kHz, and 8-10-12.5 kHz, respectively.
Conclusions: After IMRT with radiation dose constraint to the cochlea, potential long-term adverse effects of IMRT
remained subclinical. The progressive hearing loss over time was mild and could be attributed to the natural effects of
ageing. Therefore, we recommend that a dose constraint to the cochlea should be incorporated in the head and neck
radiotherapy protocols.
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Radiotherapy (RT), as single-modality treatment or
adjuvant to surgery, is a common treatment modality for
head and neck (H&N) cancer [1]. Hearing loss is one of
the adverse events of RT used in the management of
H&N malignancies as the auditory system is often
included in the treatment area. As a result, conductive
hearing loss (CHL) may be the (reversible) effect of RT
to the middle and external ear [2,3]. In addition, radiation
to the inner ear may lead to (irreversible) sensorineural
hearing loss (SNHL). Recent systematic reviews reported
incidences of SNHL of 42 ± 3% after RT [4,5]. It is well* Correspondence: n.theunissen@nki.nl
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unless otherwise stated.known that a higher dose to the cochlea is associated with
a higher risk of SNHL [1,3,4,6-9], with a minimum coch-
lear dose reported to be a risk factor of 45 Gray (Gy) [4].
Currently, the use of Intensity Modulated Radiation
Technique (IMRT) spares the organs at risk from high
radiation doses, which can improve quality of life. Such
improvements have been demonstrated in the aspect of
preservation of salivary function, trismus, and neck fibrosis
[10-12]. Equally so, IMRT will reduce the dose to the
cochlea, if possible, and therefore the risk of SNHL. The
advantage of IMRT on hearing status short-term after
treatment is reported by different authors who compared
the use of IMRT with conventional or conformal techniques
in patients with H&N cancer [4,8,12,13]. In a prospective
study of Zuur et al., 101 patients with head and neck
cancer were treated with IMRT, while sparing the innertral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Theunissen et al. Journal of Otolaryngology - Head and Neck Surgery 2014, 43:30 Page 2 of 7
http://www.journalotohns.com/content/43/1/30ear from radiation dose as much as possible [6]. The
radiation-induced hearing deterioration was found to
be rather modest, namely 1.5 decibel (dB) at speech
frequencies and 2.7 dB at ultra-high frequencies, indicat-
ing that IMRT is a safe treatment modality concerning the
hearing status.
Vascular insufficiency has been proposed as the etiology
of SNHL after radiotherapy. Animal studies showed that
this may cause lesions in the stria vascularis, in afferent
nerve endings, and in the hair cells of the cochlea [12,14].
In long-term follow-up studies showing a progressive
SNHL after conventional or conformal RT techniques, it
is hypothesized that this toxicity is either caused by an
increased progression of impaired circulation, or that
a late onset of cochlear pathology is playing a role
[2,6,15-17]. To elucidate a long-term beneficial effect
of IMRT, we evaluated in the present study the same
patients of our earlier published IMRT patient cohort
[6], at median 7.6 years post-treatment.
Methods
Between 2003 and 2006, 101 patients received IMRT for
head and neck cancer at different tumor sites, i.e. parotid
gland, oropharynx, larynx, oral cavity, maxillary sinus,
submandibular gland, nasal cavity, and external ear. Audi-
ometry was conducted in a prospective setting one week
before treatment (BT), and at a median of 3.5 months
(range 1.0-14.1 months) short-term (ST) post-treatment.
Audiometry at long-term follow-up was defined as an
audiogram at more than three years after completion of
the treatment. When more than one long-term audiom-
etry was available in one patient, the latest audiogram
was used for analysis. The study was approved by the
local ethics committee and an informed consent was
signed by all patients before treatment.
Intensity modulated radiation technique protocol
Computed tomography-generated treatment plans were
made for all patients. The computed tomography data
sets were transferred to the treatment planning systems
(UM plan, version 3.38, University of Michigan, Ann
Arbor, MI; and Pinnacle, version 7.3, Philips, Best, The
Netherlands). The clinical target volumes (primary tumor
and neck lymph nodes on both sides) and the organs at
risk (parotid glands, oral cavity, brain stem, spinal cord,
and the cochleae), were delineated on each relevant
computed tomography slice. Thereafter, RT doses to
the cochleae were calculated. For more details we refer
to the previous study [6]. None of the patients received
neoadjuvant or adjuvant chemotherapy.
Audiometry
Testing was performed in a soundproof testing room with
Decos system (Audiology Workstation). Both ears weretested. Air conduction (AC) thresholds were measured at
frequencies 0.125, 0.250, 0.5, 1, 2, 3, 4, 6, 8, 10, 12.5 kHz
and bone conduction (BC) thresholds were measured at
0.5, 1, 2, 4 kHz. Audiometric data were presented in dB
Hearing Levels (HL) at frequencies 0.125 to 8 kHz and in
dB Sound Pressure Levels (SPL) at frequencies 8 to
12.5 kHz. If measurements at 3 and 6 kHz were missing
(72% at 3 kHz, 85% at 6 kHz) interpolation of the data
was performed [11]. In case of missing measurements at
high frequencies (8% at 10 kHz and 8% at 12.5 kHz) or
when there was no response to the maximum output of
the audiometer (4% at 8 kHz, 19% at 10 kHz, and 50% at
12.5 kHz), we calculated the thresholds by extrapolating
the data, using a straight line with the same slope that was
found on average in the patients who responded at all fre-
quencies. Speech perception was not routinely measured.
Mean AC thresholds were calculated at three Pure
Tone Averages (PTAs): 0.5-1-2 kHz, 1-2-4 kHz, and 8-
10-12.5 kHz, chosen to estimate the expected degree of
disability for speech perception in quiet, speech perception
in noise, and the perception of high sounds (e.g. music,
nature), respectively. We calculated mean BC thresholds
at PTAs 0.5-1-2 kHz and 1-2-4 kHz. We used dB SPL
values for calculating the average PTA 8-10-12.5, while we
used dB HL values for the PTA of speech frequencies.
An air bone gap (ABG) was calculated by the difference
between AC and BC at PTA 0.5-1-2 kHz.
Audiological data were compared to normal hearing
levels according to the International Organization for
Standardization (ISO) standard 7029:2000 for frequencies
0.125 to 8 kHz and to a model of hearing threshold
levels based on otologically unscreened, non-occupationally
noise-exposed population in Sweden for frequencies 8,
10 and 12.5 kHz [18,19]. The ISO hearing levels were
calculated per patient and per frequency at baseline,
short-term follow-up, and long-term follow-up.
Otological examination
At long-term follow-up, both ears of a patient were
examined with otoscopy by a head and neck surgeon.
The presence or absence of the following items were
scored: tympanic membrane perforation, otitis media with
effusion (OME), acute otitis media (AOM), external otitis,
chronic otitis media (COM), atelectasis, tympanosclerosis,
stenosis of external auditory canal, and skin lesions like
erythema, desquamation, eczema, and ulcerations.
Grading of hearing impairment
Hearing impairment was expressed using the Common
Terminology Criteria for Adverse Events version 4.0
(CTCAEv4) [20]. The CTCAEv4 for hearing impairment
consist of four grades, based on threshold shifts at fre-
quencies between 1 and 8 kHz: Grade 1 = threshold shift
of 15–25 dB averaged at two contiguous frequencies in
Table 1 Patient and treatment characteristics; N = 36
patients







Short-term (months) 3.5 (1.0–14.1)
Long-term (years) 7.6 (3.7–9.3)





Parotid gland 11 (30%)
Oropharynx 9 (25%)
Larynx 8 (22%)
Oral cavity 3 (8%)
Maxillary sinus 1 (3%)
Submandibular gland 1 (3%)
Nasal cavity 1 (3%)
External ear 1 (3%)






Unknown primary 1 (3%)





Not applicable* 6 (17%)
*6 patients with recurrent or incompletely excised pleomorphic adenoma.
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Grade 2 = threshold shift of >25 dB averaged at two
contiguous frequencies in at least in one ear; Grade
3 = threshold shift of >25 dB averaged at three contiguous
frequencies in at least in one ear; Grade 4 = profound
bilateral hearing loss (>80 dB at 2 kHz and above).
Statistical analysis
The differences between hearing thresholds at baseline,
short-term follow-up, and long-term follow-up were
assessed using repeated measurement analysis. In the
repeated measures analysis we adjusted for ear, gender,
age and hearing level at the earliest of the measurements,
and time between both measurements. A p-value <0.05
was considered statistically significant. Statistical analyses




In 36 of the 101 patients (36%), audiometry at long-term
follow-up was obtained. Sixty-five patients (65%) were
deceased, lost to follow-up, or did not want to participate
anymore. Patient and treatment characteristics are
shown in Table 1. Pure tone audiometry was conducted
one week before treatment (BT), at a median of 3.5 months
(1.0-14.1) as short-term (ST) follow-up, and at a median
of 7.6 years (3.7-9.3) as long-term (LT) follow-up after
treatment. Age at short-term follow-up ranged from
32–78 years, with a median age of 59 years. Patients
were median 66 years old (39–85) at long-term follow-up.
The mean dose to the cochlea was 17.8 Gy (1.0-66.6 Gy).
Three patients received a radiation dose to the cochlea of
more than 45 Gy because of the location and stage of the
tumor: one patient had a tumor in the external hearing
canal, one patient received post-operative IMRT for a
muco-epidermoid carcinoma of the parotid gland, and
the third patient received post-operative IMRT for
pleomorphic adenoma of the parotid gland.
Mean overall hearing loss
Hearing thresholds before, at short-term follow-up, and
at long-term follow-up are summarized in Table 2.
Overall, there were no significant changes at BC thresh-
olds up to 4 kHz. At AC thresholds, hearing deteriorated
with 1.8 dB, 2.9 dB, and 7.3 dB at low, high, and ultra-high
frequencies, respectively, when audiometry at long-term
follow-up was compared with audiometry at baseline.
These differences were significant for PTA 1-2-4 (p = 0.03)
and 8-10-12.5 kHz (p < 0.001). When AC thresholds at
long-term follow-up were compared to AC thresholds at
short-term follow-up, the following deteriorations were
seen: 1.8 dB at PTA 0.5-1-2 kHz (p = 0.11), 2.3 dB at PTA
1-2-4 kHz (p = 0.02), and 4.4 dB at PTA 8-10-12.5 kHz(p = 0.01). According to the ISO, the age-related deteri-
oration in hearing between audiometry at long-term
and at short-term follow-up was expected up to 2.7 dB
at PTA 0.5-1-2 kHz, 4.8 dB at PTA 1-2-4 kHz, and
8.8 dB at PTA 8-10-12.5 kHz.
Air bone gap
In 64/72 ears (89%) both AC and BC thresholds were
measured before, at short-term follow-up, and at long-











Number of ears 72 72 67 66 66
Before treatment 20.3 (13.3) 16.7 28.6 (16.8) 25.0 75.4 (23.6) 74.8 17.4 (12.2) 14.1 24.3 (35.1) 20.8
ST after treatment 20.3 (15.4) 15.8 29.2 (18.9) 25.0 78.3 (22.3) 79.0 16.6 (12.7) 13.3 22.9 (15.1) 20.9
LT after treatment 22.1 (15.7) 18.3 31.5 (19.0) 29.2 82.7 (23.3) 82.9 17.3 (12.9) 13.3 23.2 (15.1) 20.0
Difference ST and BT 0 dB 0.6 dB 2.9 dB* −0.8 dB −1.4 dB
Difference LT and ST 1.8 dB 2.3 dB* 4.4 dB* 0.7 dB 0.3 dB
Abbreviations: ST Short-term, LT Long-term, BT Before Treatment, AC Air Conduction, BC Bone Conduction, SD Standard deviation, dB Decibel.
*Statistically significant (p < 0.05).
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of which five ears developed an ABG at short-term
follow-up and three ears at long-term follow-up (Figure 1).
In patients with an existing ABG before therapy (n = 5),
the ABG was still present (n = 3) or disappeared (n = 2) at
long-term follow-up.
Common terminology criteria for adverse events
In Table 3 hearing loss is expressed according to the
CTCAEv4 for hearing impairment. Considering the
audiogram LT after treatment compared to the audio-
gram ST after treatment, only a minor change in total
incidence was seen: 39% (grade 1–3) at short-term
follxow-up versus 36% (grade 1–3) at long-term follow-
up. See for further details Table 3.
Patients with progressive treatment-induced hearing loss
Two ears (3%, 2 patients) deteriorated more than expected
according to the ISO at both PTAs BC, implying a
treatment-induced hearing loss. At AC thresholds, three ears
(5%), four ears (6%), and seven ears (10%) deteriorated more
than expected according to the ISO at PTAs 0.5-1-2 kHz,
1-2-4 kHz, and 8-10-12.5 kHz, respectively (Table 4).
From the total cohort, three patients received a radiation
dose of more than 45 Gy to the cochlea in one ear (i.e. 51.6,
52.2 and 66.6 Gy). The hearing loss of two patients was
explicitly higher than the expected age-related deterioration
according to the ISO: at PTA 0.5-1-2 kHz BC 11.1 dBFigure 1 Number of ears with an air bone gap. Number of ears with an
short-term after treatment and long-term after treatment.versus 3.6 dB, at PTA 1-2-4 kHz BC 12.2 versus 6.5 dB, and
at PTA 8-10-12.5 kHz 13.1 versus 6.8 dB (Table 4). The
third patient lost approximately the same as expected
by ISO at PTA 0.5-1-2 and 1-2-4 kHz BC. At PTA 8-
10-12.5 kHz the measured hearing deterioration was
2.6 dB worse than expected according to the ISO.
Otological adverse events
Tympanosclerosis was the most frequently observed event
during otological examination (24%). An OME was seen
in two patients (7%), external otitis in two patients (7%),
atelectasis in three patients (10%), and skin lesions in two
patients (7%). None of patients had a perforated tympanic
membrane, COM, AOM, or stenosis of the external audi-
tory canal.
Discussion
This manuscript describes the long-term follow-up
results on hearing status in a cohort of patients with
head and neck cancer, treated with IMRT wherein the
inner ear was defined as an organ of risk [6]. To our
knowledge, this is one of the first reports describing the
long-term effects after IMRT in head and neck cancer.
Our results indicate that when the inner ear is regarded
as an organ at risk, the treatment-induced hearing loss
is modest and not progressive over time in most patients.
The average change in hearing thresholds after a median
interval of 7.6 years post-treatment was 1.8 - 2.3 dB atair bone gap at pure tone average 0.5-1-2 kHz. Measured before,
Table 3 Number of patients with hearing impairment according to the Common Terminology Criteria for Adverse
Events version 4
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total Grade 1-4
Short-term 22 (61%) 6 (17%) 4 (11%) 4 (11%) 0 14 (39%)
Long-term 23 (64%) 6 (17%) 4 (11%) 3 (8%) 0 13 (36%)
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4 kHz AC) and 4.4 dB at ultra-high frequencies (PTA
8-10-12.5 kHz) when compared to the thresholds at
short-term follow-up. There were no significant changes
at BC thresholds up to 4 kHz. Correction for presbycusis
during follow-up time according to the ISO-standard
indicated that these hearing deteriorations are part of the
natural effects of ageing, as the averaged calculated hear-
ing loss using ISO was 2.7 dB at PTA 0.5-1-2 kHz, 4.8 dB
at PTA 1-2-4 kHz, and 8.8 dB at PTA 8-10-12.5 kHz. This
is even higher than the measured deteriorations [18,19].
A recent long-term follow-up study of Tsang et al.
studied patients with nasopharyngeal cancer (NPC) treated
with IMRT or conventional therapy on their long-term
hearing status (56 ears) [21]. They concluded that there
was a BC threshold shift of 16.1 dB at 4 kHz 5 years after
IMRT treatment and that this deterioration, in general,
could not be attributed to ageing alone. In our data, no
changes were seen at BC thresholds. However, patients
treated with IMRT in the Tsang study received a dose of
50 Gy to the cochlea, whereas in our study the dose to the
cochlea was 17.8 Gy. This difference in radiation dose is
probably related to the inclusion of only patients with
NPC, whereas we included various head and neck tumor
locations without any NPC patients. Nevertheless, in our
IMRT population, sparing of the cochlea was not always
possible depending on tumor location and stage. This
happened in three patients with a tumor of the external
ear or in the parotid gland. Two of them developed a
progressive treatment-induced hearing loss at both AC
and BC thresholds at long-term follow-up (Table 4).
In our patient cohort the cochlea was regarded as an
organ at risk. However, in current practice, it is not
standard to constrain the radiation dose to the cochleae.
Even so, the Radiotherapy Oncology Group (RTOG) hasTable 4 Number of ears with treatment-related hearing loss
Number (ears) Number (ears) with
loss than expected a
PTA 0.5-1-2 kHz BC 66 2 (3%)
PTA 1-2-4 kHz BC 66 2 (3%)
PTA 0.5-1-2 kHz AC 72 3 (4%)
PTA 1-2-4 kHz AC 72 4 (6%)
PTA 8-10-12.5 kHz 67 7 (10%)
Abbreviations: PTA Pure Tone Average, AC Air Conduction, ISO International Organiz
ABG Air Bone Gap.not formulated any guidelines yet regarding dose constrains
to the cochlea in H&N treatment protocols. However, a
limitation of IMRT is that the dose given to tissues not
considered as organs at risk can be higher compared to
conventional or conformal treatment plans. A study of
Hitchcock revealed this effect: patients with head and
neck cancer were treated with IMRT (n = 21) or con-
formal RT (n = 41) [22]. As no attempt was made to limit
the dose to the cochlea, patients treated with IMRT had a
significantly higher dose delivered to the cochlea than
those treated with a conformal treatment plan. Therefore,
to better preserve hearing in most patients while using
IMRT, the cochlea should be recognized and treated as an
organ at risk. If possible, the radiation dose to the cochlea
should be limited as much as possible, preferably lower
than 45 Gy [4], although an exact safe radiation threshold
is still missing in the literature. Pacholke et al. described a
guideline for contouring the middle and inner ear [23].
These guidelines can be of practical help to radiation
oncologists.
Limitations of the study
This study has certain limitations. In the beginning the
patient group was large (101 patients), but audiometry at
long-term follow-up was only available in 36 patients
(36%), since 64% was deceased, lost to follow-up, or not
willing to participate any longer. However, given the fact
that the hearing deteriorations were rather modest, the
risk of selection bias, meaning that only patients with
subjective hearing complaints continued the follow-up, is
very low. Furthermore, time between short-term follow-
up and long-term follow-up measurements differed
between patients. However, this bias was taken into
account by adjusting for time between both audiograms
in the statistical analysis.more hearing
ccording to ISO
Explanation
2x: SNHL, RT dose to cochlea >45 Gy
2x: SNHL, RT dose to cochlea >45 Gy
2x: SNHL, RT dose to cochlea >45 Gy 1x: ABG
2x: SNHL, RT dose to cochlea >45 Gy 2x: ABG
2x: SNHL, RT dose to cochlea >45 Gy 2x: ABG
at PTA 1-2-4 kHz 3x: Unexplained
ation for Standardization, SNHL Sensorineural Hearing Loss, RT Radiotherapy,
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control group and/or a patient group treated with IMRT
with high radiation doses to the cochlea, was available.
Currently, due to the small sample size and the relatively
large number of small radiation doses to the cochlea, a
comparison between clinically relevant high and small
radiation doses could only be analyzed in a descriptive
manner. In our former study, reporting on the total
patient cohort (n = 101), we demonstrated a dose-effect
relationship between increasing radiation dose and hearing
loss. Nevertheless, due to a limited number of patients
receiving relatively high radiation doses (median cochlear
dose was 11.4 Gy), a maximum safe cochlear dose for
hearing preservation could not be calculated [6]. However,
we feel that current results are sufficient enough to
conclude that IMRT-induced hearing loss is rather
modest at both short-term and long-term follow-up,
provided that the radiation dose to the cochlea is low.
Finally, in our patient cohort, only small incidences of
ABGs were found. With this limited number of ABGs
no reliable conclusion can be made about the occurrence
of middle ear pathology long-term after IMRT. In
addition, the results of otological examination showed no
abnormalities. The incidence of 24% of tympanosclerosis
is, in our opinion, a normal percentage as it is correlated
to ear infections in the past [15]. Of the seven patients
with tympanosclerosis, five (71%) reported a medical
history of recurrent ear infections before the start of
IMRT. Future studies are needed to review the effect of
IMRT to the middle ear and Eustachian tube function.Conclusion
The current follow-up study of our earlier analyzed
patients with head and neck cancer treated with IMRT,
resulted in a smaller sample size of the patient population
and a greater diversity. Nevertheless, the importance of
regarding the cochlea as an organ at risk during IMRT
is well established. Based on our former ànd current
results, patients suffer from modest and clinical irrele-
vant IMRT-induced hearing loss at both short-term ànd
long-term follow-up, provided that the radiation dose
to the cochlea is limited. Therefore, we recommend that a
dose constraint to the cochlea should be incorporated in
the head and neck radiotherapy protocols.Abbreviations
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